We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 270

Federal Court of Appeal suggests need for Supreme Court to consider standard of review on claims construction and patentability of methods of medical treatment
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 12 2015

The Federal Court of Appeal (FCA) in Cobalt v. Bayer has explicitly called into question two central principles of Canadian patent law: the standard


Apotex denied claim for innovator's profits following PM(NOC) litigation
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 7 2015

The ongoing quest by generic pharmaceutical companies for the disgorgement of innovator profits following litigation under the PM(NOC) Regulations


Industry Canada seeks comment on proposed changes to listing requirements under the PM(NOC) Regulations
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 6 2015

On May 2, 2015, the Governor in Council issued proposed amendments to Sections 2, 3, and 4 of the Patented Medicines (Notice of Compliance


La Cour suprême du Canada rejette le premier appel entendu visant une réclamation en dommages-intérêts au titre de l’article 8
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 29 2015

Le 20 avril 2015, la Cour suprême du Canada a rejeté l’appel de Sanofi-Aventis à l’égard d’une action intentée par Apotex en vue de réclamer des


Supreme Court of Canada dismisses first section 8 damages appeal
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 28 2015

On April 20, 2015, the Supreme Court of Canada dismissed Sanofi-Aventis' appeal concerning a claim by Apotex for section 8 damages under the Patented


Applications for leave to appeal dismissed - 23 April 2015
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 23 2015

On appeal from the Court of Appeal for British Columbia. In 2007, the applicant was charged with, and convicted of, sexual assault after having


CIPO issues revised examination guidance on methods of medical treatment and dosage regimens
  • Gowling Lafleur Henderson LLP
  • Canada
  • March 20 2015

The Canadian Intellectual Property Office (CIPO) has now released Practice Notice PN 2015-01, which relates to examination of medical treatment


Canadian patent law: 2014 year in review
  • Gowling Lafleur Henderson LLP
  • Canada
  • March 18 2015

This article summarises noteworthy Canadian patent law decisions and developments from 2014. Court of Appeal addresses patent utility in Celebrex The


Re-examination: a viable alternative in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • March 13 2015

The Federal Court of Appeal recently upheld the dismissal of an appeal from a decision of a Patent Re-examination Board thus establishing that


Canadian patent law: 2014 year in review
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 26 2015

Canadian Courts have continued to address allegations that patents are invalid because they lack utility. A notable 2014 Court of Appeal decision in